Beijing Chunlizhengda Medical Instruments Co Ltd (688236) - Net Assets
Based on the latest financial reports, Beijing Chunlizhengda Medical Instruments Co Ltd (688236) has net assets worth CN¥2.99 Billion CNY (≈ $436.98 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.54 Billion ≈ $518.06 Million USD) and total liabilities (CN¥554.08 Million ≈ $81.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688236 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.99 Billion |
| % of Total Assets | 84.35% |
| Annual Growth Rate | 26.18% |
| 5-Year Change | 161.34% |
| 10-Year Change | 566.11% |
| Growth Volatility | 39.98 |
Beijing Chunlizhengda Medical Instruments Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Beijing Chunlizhengda Medical Instruments Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Beijing Chunlizhengda Medical Instrument for the complete picture of this company's asset base.
Annual Net Assets for Beijing Chunlizhengda Medical Instruments Co Ltd (2012–2024)
The table below shows the annual net assets of Beijing Chunlizhengda Medical Instruments Co Ltd from 2012 to 2024. For live valuation and market cap data, see 688236 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.82 Billion ≈ $412.85 Million |
-2.01% |
| 2023-12-31 | CN¥2.88 Billion ≈ $421.32 Million |
+5.87% |
| 2022-12-31 | CN¥2.72 Billion ≈ $397.98 Million |
+10.15% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.30 Million |
+128.71% |
| 2020-12-31 | CN¥1.08 Billion ≈ $157.98 Million |
+33.85% |
| 2019-12-31 | CN¥806.59 Million ≈ $118.03 Million |
+28.41% |
| 2018-12-31 | CN¥628.14 Million ≈ $91.92 Million |
+16.65% |
| 2017-12-31 | CN¥538.47 Million ≈ $78.80 Million |
+11.97% |
| 2016-12-31 | CN¥480.91 Million ≈ $70.37 Million |
+13.54% |
| 2015-12-31 | CN¥423.56 Million ≈ $61.98 Million |
+105.69% |
| 2014-12-31 | CN¥205.92 Million ≈ $30.13 Million |
+14.47% |
| 2013-12-31 | CN¥179.89 Million ≈ $26.32 Million |
+3.88% |
| 2012-12-31 | CN¥173.17 Million ≈ $25.34 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Chunlizhengda Medical Instruments Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2143.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.21 Billion | 42.85% |
| Common Stock | CN¥383.57 Million | 13.60% |
| Other Comprehensive Income | CN¥196.92 Million | 6.98% |
| Other Components | CN¥1.03 Billion | 36.56% |
| Total Equity | CN¥2.82 Billion | 100.00% |
Beijing Chunlizhengda Medical Instruments Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Chunlizhengda Medical Instruments Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
John B Sanfilippo & Son Inc
NASDAQ:JBSS
|
$726.73 Million |
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
$726.75 Million |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
$727.10 Million |
|
Samsung Electro Mechanics Pref
KO:009155
|
$727.11 Million |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
$726.68 Million |
|
Ray Sigorta AS
IS:RAYSG
|
$726.45 Million |
|
Hextar Global Bhd
KLSE:5151
|
$726.36 Million |
|
Wesure Global Tech Ltd
TA:WESR
|
$726.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Chunlizhengda Medical Instruments Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,877,466,853 to 2,819,902,283, a change of -57,564,570 (-2.0%).
- Net income of 124,988,009 contributed positively to equity growth.
- Dividend payments of 170,533,715 reduced retained earnings.
- Share repurchases of 12,018,864 reduced equity.
- Other comprehensive income increased equity by 196,915,661.
- Other factors decreased equity by 196,915,661.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥124.99 Million | +4.43% |
| Dividends Paid | CN¥170.53 Million | -6.05% |
| Share Repurchases | CN¥12.02 Million | -0.43% |
| Other Comprehensive Income | CN¥196.92 Million | +6.98% |
| Other Changes | CN¥-196.92 Million | -6.98% |
| Total Change | CN¥- | -2.00% |
Book Value vs Market Value Analysis
This analysis compares Beijing Chunlizhengda Medical Instruments Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 25.86x to 2.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.67 | CN¥17.30 | x |
| 2013-12-31 | CN¥0.72 | CN¥17.30 | x |
| 2014-12-31 | CN¥0.82 | CN¥17.30 | x |
| 2015-12-31 | CN¥1.22 | CN¥17.30 | x |
| 2016-12-31 | CN¥1.39 | CN¥17.30 | x |
| 2017-12-31 | CN¥1.56 | CN¥17.30 | x |
| 2018-12-31 | CN¥1.82 | CN¥17.30 | x |
| 2019-12-31 | CN¥2.32 | CN¥17.30 | x |
| 2020-12-31 | CN¥3.12 | CN¥17.30 | x |
| 2021-12-31 | CN¥6.43 | CN¥17.30 | x |
| 2022-12-31 | CN¥7.09 | CN¥17.30 | x |
| 2023-12-31 | CN¥7.46 | CN¥17.30 | x |
| 2024-12-31 | CN¥7.37 | CN¥17.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Chunlizhengda Medical Instruments Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.51%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.23x
- Recent ROE (4.43%) is below the historical average (15.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 19.10% | 32.56% | 0.52x | 1.12x | CN¥15.22 Million |
| 2013 | 18.16% | 29.55% | 0.55x | 1.12x | CN¥14.68 Million |
| 2014 | 17.98% | 27.53% | 0.56x | 1.16x | CN¥16.44 Million |
| 2015 | 8.94% | 21.35% | 0.37x | 1.13x | CN¥-4.49 Million |
| 2016 | 13.19% | 30.51% | 0.38x | 1.12x | CN¥15.35 Million |
| 2017 | 12.68% | 22.74% | 0.47x | 1.18x | CN¥14.44 Million |
| 2018 | 16.82% | 21.22% | 0.61x | 1.30x | CN¥42.83 Million |
| 2019 | 29.35% | 27.68% | 0.71x | 1.50x | CN¥156.10 Million |
| 2020 | 26.25% | 30.22% | 0.61x | 1.43x | CN¥175.41 Million |
| 2021 | 13.06% | 29.09% | 0.37x | 1.21x | CN¥75.45 Million |
| 2022 | 11.31% | 25.61% | 0.35x | 1.25x | CN¥35.75 Million |
| 2023 | 9.66% | 22.99% | 0.33x | 1.27x | CN¥-9.92 Million |
| 2024 | 4.43% | 15.51% | 0.23x | 1.23x | CN¥-157.00 Million |
Industry Comparison
This section compares Beijing Chunlizhengda Medical Instruments Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,347,771,891
- Average return on equity (ROE) among peers: 27.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Chunlizhengda Medical Instruments Co Ltd (688236) | CN¥2.99 Billion | 19.10% | 0.19x | $726.68 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $449.34 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $137.01 Million | 27.64% | 0.98x | $4.30 Billion |
| Double Medical Technology Inc (002901) | $441.78 Million | 42.71% | 0.27x | $2.63 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $577.41 Million |
| Lepu Medical Tech Beijing (300003) | $1.76 Billion | 16.64% | 0.06x | $3.87 Billion |
| INKON Life Technology Co Ltd (300143) | $810.78 Million | 0.80% | 0.23x | $1.23 Billion |
| Edan Instruments Inc (300206) | $2.01 Billion | 8.07% | 0.19x | $1.26 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $89.93 Million | 36.68% | 0.42x | $685.28 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $105.32 Million | 39.32% | 0.45x | $534.16 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.36 Billion |
About Beijing Chunlizhengda Medical Instruments Co Ltd
Beijing Chunlizhengda Medical Instruments Co., Ltd. engages in the research and development, production, and trading of surgical implants, instruments, and related products in the People's Republic of China. The company offers implantable orthopedic medical devices, joints, dentures, spine, sports medicine, trauma and orthopedic surgical instruments. It sells its products through distributors, or… Read more